13F Holdings
中文EN

VCYT VERACYTE, INC.

Services-Medical Laboratories · Nasdaq · SEC CIK 1384101 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.5%
TTM net income YoY318.4%
TTM EPS YoY305.3%
Revenue 3-yr CAGR19.2%
Net income 3-yr CAGR—

Margins

Gross margin72.0%
Operating margin17.1%
Net margin21.8%
FCF margin27.8%
EBITDA margin20.8%

Returns

ROE9.4%
ROA8.6%
ROIC (approx.)9.1%
Asset turnover0.40x

Leverage & solvency

Liabilities / assets8.9%
Debt / equity0.00x
Current ratio5.56x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.37x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$517.14M$445.76M$361.05M$296.54M$219.51M
Gross profit$362.53M$298.14M$229.68M$175.68M—
R&D expense$70.81M$69.29M$57.30M$40.60M$29.84M
SG&A expense$110.78M$110.61M$86.23M$73.20M$101.35M
Operating income$57.78M$16.14M-$85.80M-$41.08M-$81.90M
Pretax income$68.20M$25.74M-$76.61M-$36.43M-$81.65M
Income tax$1.85M$1.61M-$2.21M$133,000-$6.09M
Net income$66.35M$24.14M-$74.40M-$36.56M-$75.56M
EBITDA$79.19M$39.60M-$58.61M-$15.15M-$62.31M
EPS (basic)0.840.32-1.02-0.51-1.11
EPS (diluted)0.820.31-1.02-0.51-1.11
Weighted avg. shares (diluted)80.57M78.16M72.64M71.55M67.89M
Balance sheet
Cash & equivalents$362.58M$240.63M$216.45M$155.00M$173.95M
Short-term investments$50.31M————
Receivables$44.66M$46.52M$40.38M$44.02M$41.46M
Inventory$20.55M$21.75M$16.13M$14.29M$11.22M
Current assets$488.38M$372.27M$285.62M$248.64M$243.10M
PP&E, net$22.19M$22.95M$20.58M$17.70M$15.10M
Goodwill$767.15M$745.80M$702.98M$695.89M$707.90M
Intangibles$89.15M$102.30M$88.59M$174.87M$202.73M
Total assets$1.41B$1.30B$1.11B$1.16B$1.19B
Current liabilities$59.94M$78.63M$61.24M$62.61M$64.15M
Short-term debt———$0$1.13M
Long-term debt————$0
Total debt————$1.13M
Total liabilities$96.44M$124.07M$70.80M$81.22M$91.31M
Shareholders' equity$1.31B$1.18B$1.04B$1.08B$1.10B
Net debt————-$172.82M
Shares outstanding79.36M77.77M73.26M71.96M71.12M
Cash flow statement
Operating cash flow$136.31M$75.10M$44.22M$7.54M-$31.62M
Capital expenditure$9.68M$11.29M$9.96M$8.55M$5.38M
Free cash flow$126.63M$63.81M$34.26M-$1.01M-$37.00M
Investing cash flow-$9.21M-$56.27M$15.11M-$29.39M-$739.21M
Financing cash flow-$4.22M$4.90M$2.84M$3.49M$596.32M
Depreciation & amortization$21.41M$23.46M$27.19M$25.93M$19.59M
Stock-based compensation$43.60M$36.25M$33.14M$26.73M$22.52M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.